Cargando…

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma

BACKGROUND: Medulloblastoma (MB) is the most common cerebellar malignancy during childhood. Among MB, MYC-amplified Group 3 tumors display the worst prognosis. MYC is an oncogenic transcription factor currently thought to be undruggable. Nevertheless, targeting MYC-dependent processes (i.e. transcri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pitolli, Consuelo, Marini, Alberto, Guerra, Marika, Pieraccioli, Marco, Marabitti, Veronica, Palluzzi, Fernando, Giacò, Luciano, Tamburrini, Gianpiero, Cecconi, Francesco, Nazio, Francesca, Sette, Claudio, Pagliarini, Vittoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440921/ https://www.ncbi.nlm.nih.gov/pubmed/37599362 http://dx.doi.org/10.1186/s13046-023-02790-2

Ejemplares similares

Non-Canonical Splicing and Its Implications in Brain Physiology and Cancer
por: Pitolli, Consuelo, et al.
Publicado: (2022)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
por: Madhavan, Krishna, et al.
Publicado: (2022)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023)

Pathological implications of metabolic reprogramming and its therapeutic potential in medulloblastoma
por: Marabitti, Veronica, et al.
Publicado: (2022)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification
por: Ćwiek, Paulina, et al.
Publicado: (2014)

Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors
por: Bielli, Pamela, et al.
Publicado: (2019)

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

MBRS-26. CDK7 MEDIATED TRANSCRIPTIONAL PROCESSIVITY OF DNA REPAIR NETWORKS REGULATES SENSITIVITY TO RADIATION IN MYC DRIVEN MEDULLOBLASTOMA
por: Veo, Bethany, et al.
Publicado: (2020)

CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1
por: Panzeri, Valentina, et al.
Publicado: (2023)

The androgen receptor couples promoter recruitment of RNA processing factors to regulation of alternative polyadenylation at the 3' end of transcripts
por: Caggiano, Cinzia, et al.
Publicado: (2022)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

Cdk2: a key regulator of the senescence control function of Myc
por: Hydbring, Per, et al.
Publicado: (2010)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
por: Huang, Chun-Hao, et al.
Publicado: (2014)

MYC Modulation around the CDK2/p27/SKP2 Axis
por: Hydbring, Per, et al.
Publicado: (2017)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
por: Wang, Dan, et al.
Publicado: (2022)

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Regulatory functions of the Mediator kinases CDK8 and CDK19
por: Fant, Charli B., et al.
Publicado: (2018)

c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer
por: Caggiano, Cinzia, et al.
Publicado: (2019)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Should I stay or should I go? Spatio-temporal control of cellular anchorage by hematopoietic factors orchestrates tumor metastatic cascade
por: Marabitti, Veronica, et al.
Publicado: (2023)

CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
por: Bisteau, Xavier, et al.
Publicado: (2013)

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
por: Wood, Daniel J., et al.
Publicado: (2019)

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
por: Lei, Hanqi, et al.
Publicado: (2021)

Combinatorial control of Spo11 alternative splicing by modulation of RNA polymerase II dynamics and splicing factor recruitment during meiosis
por: Cesari, Eleonora, et al.
Publicado: (2020)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules
por: Dannappel, Marius Volker, et al.
Publicado: (2019)

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
por: Majumdar, Abir, et al.
Publicado: (2021)

De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
por: Tarrado‐Castellarnau, Míriam, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ls6q5qfod7eiks49p6n1ib6oto